HONG KONG, Nov. 16, 2025 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) announced that its AK152, a novel bispecific antibody targeting both amyloid-beta (Aβ) and blood-brain barrier (BBB) expressed receptor, has been granted approval by the National Medical Products Administration (NMPA) to...
Hence then, the article about akeso s bispecific antibody targeting ab and bbb expressed receptor approved for alzheimer s disease clinical trials in china was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso's Bispecific Antibody Targeting Aβ and BBB-Expressed Receptor Approved for Alzheimer's Disease Clinical Trials in China )
Also on site :
- Ann Godoff, Penguin Press Founder and Editor, Dies at 76
- WI vs SA Dream11 Prediction Today Match, Dream11 Team Today, Fantasy Cricket Tips, Playing XI, Pitch Report, Injury Update- ICC T20 World Cup 2026, Match 47
- Megan Thee Stallion Has One Question for Juvenile About Their Rumored ‘B.B.B.’ Remix: ‘When You Gonna Drop It?’